摘要
目的研究程序性死亡因子配体-1(PD-L1)、人骨髓内皮细胞标记物-1(HBME-1)在甲状腺乳头状癌组织中的表达及临床意义。方法选取2017年4月至2019年5月该院收治的102例甲状腺乳头状癌患者为研究对象,手术切除病灶组织及癌旁正常组织,分别作为观察组(n=102)与对照组(n=102)。通过免疫组化染色,观察两组PD-L1、HBME-1表达情况。通过单因素及多因素分析PD-L1、HBME-1表达量与甲状腺乳头状癌一般特征的关系。结果PD-L1在观察组中阳性率为69.61%(71/102),明显高于对照组的15.69%(16/102),差异有统计学意义(χ^2=60.625,P<0.001)。HBME-1在观察组中阳性率为73.53%(75/102),明显高于对照组的6.86%(7/102),差异有统计学意义(χ^2=94.291,P<0.001)。多因素分析结果显示,PD-L1及HBME-1表达阳性是肿瘤发生淋巴结转移及侵犯包膜的危险因素(P<0.05)。结论PD-L1与HBME-1在甲状腺乳头状癌组织中均处于高表达状态,且与患者肿瘤发生淋巴结转移及侵犯包膜密切相关,PD-L1与HBME-1可辅助诊断患者肿瘤发展情况。
Objective To study the expression and clinical significance of programmed death ligand-1(PD-L1)and human bone marrow endothelial cell marker-1(HBME-1)in thyroid papillary carcinoma.Methods The tumor tissues(experimental group)and adjacent normal tissues(control group)collected from 120 patients with thyroid papillary carcinoma in Leshan Hospital of Traditional Chinese Medicine from April 2017 to May 2019 were enrolled.The expression of PD-L1 and HBME-1 in the two groups were observed by immunohistochemical staining.The relationships between the expression of PD-L1,HBME-1 and the general characteristics of papillary thyroid carcinoma were analyzed by univariate and multivariate analysis.Results The positive rate of PD-L1 in the experimental group was significantly higher than that in the control group[69.61%(71/102)vs.15.69%(16/102),χ^2=60.625,P<0.001].The positive rate of HBME-1 in the experimental group was significantly higher than that in the control group[73.53%(75/102)vs.6.86%(7/102),χ^2=94.291,P<0.001].Multivariate analysis showed that the positive expression of PD-L1 and HBME-1 were risk factors for lymph node metastasis and tumor invasion(P<0.05).Conclusion PD-L1 and HBME-1 express highly in papillary thyroid carcinoma,and closely relate to tumor lymph node metastasis and tumor invasion.Moreover,the two biomarkers could be used to evaluated tumor development.
作者
周翼
吴林军
雷建东
ZHOU Yi;WU Linjun;LEI Jiandong(Department of Clinical Laboratory,Leshan Hospital of Traditional Chinese Medicine,Leshan,Sichuan 614000,China)
出处
《国际检验医学杂志》
CAS
2020年第16期2003-2007,共5页
International Journal of Laboratory Medicine